Clinical trial
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined…
NCT00226993 · Stanford University, Other · Withdrawn
Key facts
| NCT number | NCT00226993 |
|---|---|
| Title | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. |
| Official title | Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides |
| Lead sponsor | Stanford University, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Mycosis Fungoides |
| Intervention type | Drug |
| Interventions | CPG 7909 |
| Enrollment | 0 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2006 |
| First posted | Sep 27, 2005 |
| Last update posted | Dec 1, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: